Target Discovery and Validation Reviews and Protocols

Volume 1, Emerging Strategies for Targets and Biomarker Discovery

  • Mouldy Sioud

Part of the Methods in Molecular Biology™ book series (MIMB, volume 360)

Table of contents

  1. Front Matter
    Pages i-xii
  2. Ramaswamy Narayanan
    Pages 13-31
  3. Seiya Imoto, Yoshinori Tamada, Christopher J. Savoie, Satoru Miyanoaa
    Pages 33-56
  4. Robert M. Beaty, Mads Gronborg, Jonathan R. Pollack, Anirban Maitra
    Pages 57-89
  5. Therese Sørlie
    Pages 91-114
  6. Øystein Røsok, Mouldy Sioud
    Pages 115-129
  7. Sahohime Matsumoto, Makoto Miyagishi, Kazunari Taira
    Pages 131-142
  8. Masayuki Sano, Kazunari Taira
    Pages 143-153
  9. Louis-Marie Houdebine
    Pages 163-202
  10. Preethi Vijayaraj, Goran Söhl, Thomas M. Magin
    Pages 203-251
  11. Dag K. Skovseth, Axel M. Küchler, Guttorm Haraldsen
    Pages 253-268
  12. Per Ole Iversen, Dag R. Sørensen
    Pages 269-275
  13. François Le Naour
    Pages 327-334
  14. Lina Cekaite, Eivind Hovig, Mouldy Sioud
    Pages 335-348
  15. Back Matter
    Pages 349-354

About this book

Introduction

Target discovery is a field that has existed for several years but is so vibrant today because of the recent progress in our understanding of the molecular mechanisms of many human diseases and the technical advances in target identification and validation. More sophisticated gene profiling technologies, such as DNA microarrays and serial analysis of gene expression, permit rapid identification of lead targets. Moreover, analysis of gene networks in living organisms allows the identification of target genes that operate in defined physiological pathways. With the sequencing of several genomes completed and the rapidly growing gene expression databases, there is now greater impetus than ever before for in silico discovery of therapeutic targets. Also, recent advances in genetic technologies have increased our ability to generate mouse models for human diseases. The implications of these genetically modified animals in drug development are several, including identification of new drug targets, predicting efficacy, and uncovering possible side effects. Together, these recent technical advances should allow researchers to make the most informed choice early and advance the chosen targets toward clinical studies. Regarding cancers, any difference between a cancer and a normal cell could potentially be exploited as a therapeutic target. The hope is that drugs targeting specific constituents or pathways in cancer cells will provide more effective therapy, either alone or in combination with other currently used anticancer drugs. In addition to drug targets, identifying new target antigens remains as much of a challenge as improving tumor vaccines already in the clinic.

Keywords

DNA Microarray Proteomics angiogenesis bioinformatics classification gene expression genes molecular mechanisms translation

Editors and affiliations

  • Mouldy Sioud
    • 1
  1. 1.Department of Immunology, Institute for Cancer Research, The Norwegian Radium HospitalUniversity of OsloOsloNorway

Bibliographic information

  • DOI https://doi.org/10.1385/1597451657
  • Copyright Information Humana Press 2007
  • Publisher Name Humana Press
  • eBook Packages Springer Protocols
  • Print ISBN 978-1-58829-656-6
  • Online ISBN 978-1-59745-165-9
  • Series Print ISSN 1064-3745
  • Series Online ISSN 1940-6029
  • About this book
Industry Sectors
Health & Hospitals
Biotechnology
Pharma